乐
乐观
乐观 · 25%RGC
$19.32
情景价格
$6.908
-0.343 (-4.97%)收盘时
Loading chart…
- 最高
- 7.250
- 开盘
- 7.150
- 成交量加权均价
- 6.96
- 成交量
- 181.03K
- 市值
- 45.81M
- 最低
- 6.720
- 成交额
- 1.26M
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
AI 分析 of Regencell Bioscience Holdings Ltd (RGC)
卖出Regencell Bioscience Holdings Ltd is not a good buy right now due to its significant recent decline and poor financial metrics. The current price is $7.67, with a 5-day change of -20.02% and a year-to-date decline of -62.66%. The RSI is at 34.119, indicating that the stock is oversold. The main risk is the negative earnings performance reflected in the P/E ratio of -415.58, suggesting ongoing financial struggles.
分析师评级（15）
买入
9 买入
5 持有
1 卖出
当前: 6.91
最低
—
平均
—
最高
—
估值指标
Regencell Bioscience Holdings Ltd（RGC）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。
Alphio AI 对 RGC 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
2.007-01seekingalphaRegencell Bioscience Shares Surge 35% Amid Short Squeeze
7.006-23PRnewswireRegencell Bioscience Faces Class Action Lawsuit
7.006-23GlobenewswireRegencell Bioscience Class Action Alert for Investors
- 7.006-23PRnewswire
Regencell Securities Class Action Reminder
- 7.006-22Globenewswire
Regencell Faces Class Action Lawsuit for Investor Rights
RGC 常见问题 —— 由 Alphio AI 解答
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
Regencell Bioscience Holdings Ltd is not a good buy right now due to its significant recent decline and poor financial metrics. The current price is $7.67, with a 5-day change of -20.02% and a year-to-date decline of -62.66%. The RSI is at 34.119, indicating that the stock is oversold. The main risk is the negative earnings performance reflected in the P/E ratio of -415.58, suggesting ongoing financial struggles.
15 analysts cover RGC: 9 rate it Buy, 5 Hold and 1 Sell.
社区
更多 ↗暂无帖子
注册或登录后参与讨论本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。